HKU Scholars Hub: Browsing DSpace

Browsing by Author Gane, E

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 52 to 71 of 72 < previous next >

Title	Author(s)	Issue Date	Views
Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results Proceeding/Conference:Journal of Hepatology	Gane, E Lim, YS Cloutier, D Shen, L Cathcart, A Ding, X Pang, P Huang, S Yuen, RMF	2021
Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use Proceeding/Conference:Journal of Hepatology	Gane, E Seto, WKW Janssen, H Carantu, FA Kim, HJ Abdurakhmanov, D Nishiguchi, S Andrzej, H Bae, H Mo, S Suri, V Gaggar, A Flaherty, JF Kao, JH Brunetto, M Ferret, MB	2018	88
Safety, pharmacokinetics (PK), and antiviral activity of the capsid assembly modulator (CAM) ALG-000184 in Asian and non-Asian subjects with chronic hepatitis B (CHB) Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International	Yuen, RMF Agarwal, K Gane, E Jucov, A Schwabe, C Le, K Massetto, B Westland, C Zhang, QL Blatt, L Lin, T-I Chanda, S Mcclure, M Fry, J	2022
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial Journal:The Lancet Gastroenterology & Hepatology	Yuen, RMF Zhou, X Gane, E Schwabe, C Tanwandee, T Feng, S Jin, YY Triyatni, M Lemenuel-Diot, A Cosson, V Xue, ZH Kazma, R Bo, QY	2021
Safety, tolerability and pharmacokinetics (pk) of single and multiple doses of alg-010133, an s-antigen transport inhibiting oligonucleotide polymer (stops) for the treatment of chronic hepatitis B Proceeding/Conference:Journal of Hepatology	Gane, E Yuen, RMF Yogaratnam, J Le, K Vuong, J Christopher, W Gohil, V Schwabe, C Agarwal, K Jucov, A Liu, JW Lin, T-I Blatt, L Chanda, S McClure, M Fry, J	2021	9
Safety, tolerability, pharmacokinetics and antiviral activity of AL-3778, a first-in-class, HBV core assembly modulator alone and in combination with peginterferon-alpha 2A, in treatment naive HBeAg-positive chronic hepatitis B patients Proceeding/Conference:Hepatology International	Kennedy, W Yuen, RMF Kim, DJ Weilert, F Chan, HLY Lalezari, J Hwang, SG Nguyen, T Westland, C Kakuda, T Brown, N Klumpp, K Flores, L Talloen, W Lenz, O Gane, E van Remoortere, P Chandra, S Fry, J	2017	116
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Proceeding/Conference:Journal of Hepatology	Gane, E Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O De Ridder, F Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2021	1
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B (CHB) shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International	Gane, E Locarnini, S Lim, TH Strasser, SI Sievert, W Cheng, W Thompson, AJ Given, BD Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont, M Lenz, O Ridder, FD Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, R Yuen, RMF	2022
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold Proceeding/Conference:Journal of Hepatology	Yuen, RMF Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Gane, E	2019	73
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment Proceeding/Conference:Journal of Hepatology	Gane, E Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2020	3
Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial Proceeding/Conference:Hepatology	Lai, CL Gane, E Liaw, YF Thongsawat, S Wang, YM Chen, Y Heathcote, J Rasenack, J Bzowej, N Naoumov, N Chao, G Fielman, B Brown, N and the GLOBE Study Group, .	2005
Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: Results from the GLOBE study Proceeding/Conference:Journal of Hepatology	Thongsawat, S Lai, CL Gane, E Chao, G Fielman, B Brown, N GLOBE Investigator Group, .	2006	117
Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients Proceeding/Conference:Hepatology	DiBisceglie A, A Lai, CL Gane, E Chen, YC Thongsawat, S Wang, YM Chen, YG Heathcote, EJ Zeuzem, S Rasenack, J Bzowej, N Han, SH Naoumov, N Hwang, SG Lim, SG Chao, GC Fielman, BA Brown, NA Study Group The GLOBE,	2006	100
Telbivudine versus lamivudine in patients with chronic hepatitis B Journal:New England Journal of Medicine	Lai, CL Gane, E Liaw, YF Hsu, CW Thongsawat, S Wang, Y Chen, Y Heathcote, EJ Rasenack, J Bzowej, N Naoumov, NV Di Bisceglie, AM Zeuzem, S Moon, YM Goodman, Z Chao, G Constance, BF Brown, NA	2007	135
Telbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of Response Proceeding/Conference:Hepatology International	Lai, CL Gane, E Hsu, CW Chen, YC Thongsawat, S Wang, Y Chen, Y Naoumov, N Han, SH Hwang, SG Lim, SG Brown, NA	2007	163
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial Journal:The Lancet Gastroenterology & Hepatology	Chan, HL Fung, S Seto, WKW Chuang, WL Chen, CY Kim, HJ Hui, AJ Janssen, H Chowdhury, A Tsang, TY Rajiv, M Gane, E Flaherty, J Massetto, B Gaggar, A Kitrinos, KM Lin, L Subramanian, GM McHutchison, J Lim, YS Acharya, SK Agarwal, K	2016	76
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial Journal:The Lancet Gastroenterology & Hepatology	Buti, M Gane, E Seto, WKW Chan, HL Chuang, WL Stepanova, T Hui, AJ Lim, YS Mehta, R Janssen, H Acharya, SK Flaherty, J Massetto, B Cathcart, AL Kim, K Gaggar, A Subramanian, GM McHutchison, J Pan, C Brunetto, M Izumi, N Marcellin, P	2016
The Capsid Assembly Modulator ALG-000184 dosed for 28 days was well tolerated and rapidly reduced viral markers in subjects with chronic hepatitis B, including HBsAg in a subset of HBeAg positive subjects with elevated baseline ALT Proceeding/Conference:Hepatology International	Gane, E Yuen, MF Agarwal, K Juov, A Hou, J Niu, J Massetto, B Le, K Lin, TI McClure, M	31-Mar-2023
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients Journal:Hepatology International	Liu, M Tseng, TC Jun, DW Yeh, ML Trinh, H Wong, GLH Chen, CH Peng, CY Kim, SE Oh, H Kwak, MS Cheung, M Toyoda, H Hsu, YC Jeong, JY Yoon, EL Ungtrakul, T Zhang, J Xie, Q Ahn, SB Enomoto, M Shim, JJ Cunningham, C Jeong, SW Cho, YK Ogawa, E Huang, R Lee, DH Takahashi, H Tsai, PC Huang, CF Dai, CY Tseng, CH Yasuda, S Kozuka, R Li, J Wong, C Wong, CC Zhao, C Hoang, J Eguchi, Y Wu, C Tanaka, Y Gane, E Tanwandee, T Cheung, R Yuen, MF Lee, HS Yu, ML Kao, JH Yang, HI Nguyen, MH	2021	11
Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine Proceeding/Conference:Hepatology	Lai, CL Gane, E Hsu, CW Thongsawat, S Wang, YM Chen, YG Heathcote, EJ Rasenack, J Bzowej, N Naoumov, N Zeuzem, S Di Bisceglie, A Chao, GC Barbara, A Constance, F Brown, NA Study Group The GLOBE.,	2006	162

Showing results 52 to 71 of 72 < previous next >